Assembly Biosciences, Inc. has announced the approval of a new cash bonus plan, the 2026 Corporate Bonus Plan, effective January 1, 2026. This plan aims to motivate, retain, attract, and reward employees through performance-based incentive compensation goals. The plan will reward employees who commence employment by October 31 of the performance period and are designated for participation by the Compensation Committee or the Chief Executive Officer. The plan includes cash bonuses based on the achievement of corporate and individual performance objectives, with the potential for bonuses to range from 0 to 1.5 times a participant's target bonus. Additionally, the Compensation Committee approved an increase in the bonus target for CEO Jason A. Okazaki from 60% to 65% of his base salary, effective for the fiscal year 2026. This adjustment reflects the company's commitment to aligning executive compensation with performance metrics and enhancing retention of key leadership. The plan is designed to foster a culture of accountability and performance within the organization, ensuring that employees are rewarded for their contributions to the company's success.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.